Article: article from journal or magazin.
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.
Aids Research and Human Retroviruses
Swiss HIV Cohort Study
Battegay M., Bernasconi E., Böni J., Bucher HC., Bürgisser P., Calmy A., Cattacin S., Cavassini M., Dubs R., Egger M., Elzi L., Fischer M., Flepp M., Fontana A., Francioli P., Furrer H., Fux CA., Gorgievski M., Günthard HF., Hirsch HH., Hirschel B., Hösli I., Kahlert C., Kaiser L., Karrer U., Kind C., Klimkait T., Ledergerber B., Martinetti G., Müller N., Nadal D., Paccaud F., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schmid P., Schultze D., Schüpbach J., Speck R., de Tejada BM. , Taffé P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S.
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish. - WOS number: 000284311900012
Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA >400 copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available.
Adult, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/adverse effects, Antiretroviral Therapy, Highly Active/adverse effects, Antiretroviral Therapy, Highly Active/methods, Cohort Studies, Female, HIV Infections/drug therapy, HIV Protease Inhibitors/administration & dosage, HIV Protease Inhibitors/adverse effects, HIV-1/isolation & purification, Humans, Male, Middle Aged, RNA, Viral/blood, Salvage Therapy/adverse effects, Salvage Therapy/methods, Switzerland, Time Factors, Treatment Failure, Treatment Outcome, Viral Load
Web of science
Last modification date